Study shows real world efficacy of rivaroxaban

Results of the XANTUS trial shows that rivaroxaban is performing ‘in the real world’ much as it did in the pivotal ROCKET AF trial, says a vascular physician.

The observational trial results, for 6784 patients with non-valvular atrial fibrillation taking rivaroxaban taking the drug for a mean of 329 days, show that treatment-emergent major bleeding occurred in 128 patients (2.1 events per 100 patient years).